Feb 3, 2020
CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application
Nov 14, 2019
CORMEDIX INC. REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Nov 6, 2019
CorMedix Inc. Announces a Change to its Senior Leadership
Oct 21, 2019
CORMEDIX COMPLETES SUCCESSFUL CMC INTERACTION WITH THE FDA
Sep 30, 2019
CORMEDIX INC. ANNOUNCES EXERCISES OF OUTSTANDING WARRANTS
Aug 15, 2019
CORMEDIX INC. ANNOUNCES EXCHANGE AGREEMENT WITH ITS LARGEST INVESTOR
Jul 17, 2019
CORMEDIX PRESENTS AT FDA PUBLIC MEETING ON THE LIMITED POPULATION PATHWAY FOR ANTIBACTERIAL AND ANTIFUNGAL DRUGS
Jul 9, 2019
CORMEDIX RECEIVES ENCOURAGING FDA FEEDBACK ON NEUTROLIN® LOCK-IT-100 DATA
Jul 8, 2019
CORMEDIX ANNOUNCES PUBLICATION OF TAUROLIDINE PRE-CLINICAL ONCOLOGY DATA IN “INVESTIGATIONAL NEW DRUGS” JOURNAL
Jun 26, 2019
CorMedix Inc. Set to Join the Russell 2000® Index
Jun 10, 2019
CorMedix Inc. to Ring NYSE Closing Bell on Monday, June 10
May 14, 2019
CORMEDIX INC. REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
May 10, 2019
CORMEDIX ANNOUNCES PRESENTATION OF LOCK-IT-100 STUDY RESULTS AT NATIONAL KIDNEY FOUNDATION SPRING 2019 MEETING
Apr 22, 2019
CORMEDIX ANNOUNCES ONLINE PRE-CLINICAL ABSTRACT AT THE UPCOMING ANNUAL MEETING OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY
Apr 17, 2019
CORMEDIX COMPLETES SALE OF $5.4 MILLION OF NOL TAX BENEFITS THROUGH NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM
Apr 11, 2019
CORMEDIX NOTIFIED OF COMPLIANCE WITH NYSE AMERICAN LISTING REQUIREMENTS
Mar 25, 2019
CORMEDIX CONFIRMS PREVIOUSLY ANNOUNCED ONE-FOR-FIVE REVERSE STOCK SPLIT
Mar 21, 2019
CORMEDIX INC. ANNOUNCES APPOINTMENT OF PHOEBE MOUNTS AS EXECUTIVE VICE PRESIDENT AND GENERAL COUNSEL
Mar 14, 2019
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS, ANNOUNCES REVERSE STOCK SPLIT AND PROVIDES BUSINESS UPDATE
Mar 4, 2019
CORMEDIX INC. APPOINTS ALAN W. DUNTON, M.D. TO BOARD OF DIRECTORS
